<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee180371f04">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <namePart>General Government Division</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">1994-05-13</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
</physicalDescription>
<classification authority="sudocs">GA 1.13:GGD-94-139</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-GGD-94-139</identifier>
<identifier type="local">P0b002ee180371f04</identifier>
<identifier type="former package identifier">f:gg94139</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-23</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-GGD-94-139</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-GGD-94-139</accessId>
 <reportNumber>GGD-94-139</reportNumber>
 <subject>Tax credit</subject>
 <subject>Tax administration</subject>
 <subject>Pharmaceutical industry</subject>
 <subject>Corporations</subject>
 <subject>Tax shelters</subject>
 <subject>Research and development</subject>
 <subject>Tax return audits</subject>
 <subject>Pharmacological research</subject>
 <subject>Tax law</subject>
 <subject>Investments</subject>
 <identifier>IRS Industry Specialization Program</identifier>
 <type>Chapter Report</type>
 <seriesAbbrev>GGD</seriesAbbrev>
</extension>
<titleInfo>
 <title>Tax Policy: Pharmaceutical Industry&apos;s Use of the Research Tax Credit</title>
</titleInfo>
<abstract>In 1991, Congress enacted the research and experimentation tax credit to
encourage businesses to do research. GAO estimates that the
pharmaceutical industry earned $1.24 billion worth of these tax credits
between 1981 and 1990. The industry&apos;s credits as a share of the credits
earned by all industries rose from four percent in 1981 to 12 percent in
1990. These credits were earned primarily by large companies--those with
assets of $250 million or more. The biotechnology sector benefitted very
little from the tax credit. The research and experimentation tax credit
is difficult for the Internal Revenue Service (IRS) to administer
because (1) auditors have to distinguish stages of research, (2) audit
issues are often highly technical, and (3) successive proposed
regulations cause uncertainty.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GGD-94-139/html/GAOREPORTS-GGD-94-139.htm</url>
</location>
<identifier type="preferred citation">GAO/GGD-94-139</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-GGD-94-139</url>
</location>
<note>Chapter Report</note>
<extension>
 <searchTitle>GAO/GGD-94-139; Tax Policy: Pharmaceutical Industry&apos;s Use of the Research Tax Credit;
            </searchTitle>
</extension>
<subject>
 <topic>Tax credit</topic>
 <topic>Tax administration</topic>
 <topic>Pharmaceutical industry</topic>
 <topic>Corporations</topic>
 <topic>Tax shelters</topic>
 <topic>Research and development</topic>
 <topic>Tax return audits</topic>
 <topic>Pharmacological research</topic>
 <topic>Tax law</topic>
 <topic>Investments</topic>
 <topic>IRS Industry Specialization Program</topic>
</subject>
</mods>